We are dedicated to developing and commercializing therapies that transform patient lives and advance patient care by changing treatment paradigms in thrombosis and other hematologic diseases.
Our two lead assets are Bevyxxa® (betrixaban), and andexanet alfa. In addition, cerdulatinib is our investigational Syk/JAK inhibitor to treat hematologic cancers. These wholly owned compounds come from our own internal research efforts and represent important advances to address significant unmet needs.
We are employing novel strategies that may increase the likelihood of clinical, regulatory and commercial success of our potentially lifesaving therapies.
- Andexanet alfa – which was granted Breakthrough Therapy designation by the FDA, is a recombinant protein designed to reverse anticoagulant activity in patients treated with a Factor Xa inhibitor. Andexanet is being developed to address major and sometimes fatal bleeding associated with Factor Xa inhibitors. Learn more.
- Cerdulatinib – our oral, dual Syk-JAK inhibitor, is being developed to treat patients with hematologic cancers who do not respond to current therapies. Learn more.